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The achievements of the modern genetics and mo­
lecular biology have significantly broadened the know­
ledge on the breast cancer (BC) [1]. Nowadays there are 
5 types of this disease, one of which is estrogen receptor 
(ER), progesterone receptor (PR), and HER­2/neu­
negative BC, so­called triple­receptor­negative tumors. 
The results of the clinical observations prove that this type 
of BC is characterized by the negative forecast of the 
disease course, high risk of relapse and remote metas­
tasis and by the low survival of the patients respectively 
[2]. As there are no receptors of steroid hormones and 
HER­2/neu, these tumors are irresponsive to hormonal 
and targeted therapy. Usually during the treatment of this 
type of the BC the polychemotherapy (PCT) scheme 
involving anthracyclines, more often — the АС ones (with 
further possible involvement of taxanes to the scheme), 
is applied [3, 4]. At the same time, there are data accor­
ding to which a rather substantial percent of the tumors 
is irresponsive to the standard accepted chemotherapy 
schemes [5]. Due to this fact, the researches directed 
on individual chemotherapy with the patients with the 
triple­receptor­negative tumors are currently in spite 
of interest. It is known that the BC resistance to the an­
thracycline antibiotics, phytogenic alkaloids and taxanes 
is connected with the increased expression of P­glyco­
protein (Р­gp). Expression of glutathione­S­transferase 
(GST) and metallothioneins (МТ) in the breast cancer 
cells characterizes the low responsiveness to cisplatin, 
chlorambucil and to other alkylating agents [6–9].
Thus, the aim of our research was the compara­
tive study of the efficiency of the application of various 
schemes of antitumor therapy selected by immunohis­
tochemical study of peculiar features of the expression 
of proteins associated with the drug resistance (P­gp, 
GST and МТ) of the patients with the triple­receptor­
negative (RE–, RP–, HER­2/neu–) BC. Our research 
included 60 patients suffering from the BC with triple­
receptor­negative tumors. All of these patients were 
in the pre­menopause condition and the disease stage 
corresponded to the criterion T1–2N0–2M0.
Immunohistochemical studies of the expression 
of RE, RP, P­gp, GST and МТ were carried out on the 
trepan­biopsy materials obtained prior to the beginning 
of the treatment with the application of the generally ac­
cepted method [10] with the use of specific MoAbs (Dako 
Cytomation, Denmark, and Chemicon International, 
Europe). At the beginning of the treatment all patients un­
derwent a large fractional ТγТ and afterwards — a radical 
surgery. Statistical analysis was carried out with the help 
of the set of STATISTICA 6.0 software. Student’s t­crite­
rion was used for evaluation defferences significance, 
p < 0.05 was considered significant.
Depending on the expression patterns of P­gp, 
GST and MT on BC cells, the BC patients were divided 
into 4 groups: 
1) Control group (n = 17): the patients were treated 
according to the standard scheme adriablastin + cy­
clophosphamide (АС); BC cells were negative by P­gp, 
GST and МТ expression.
2) The patients (n = 13) were treated according 
to the schemes taxoter + adriablastin (ТА) (n = 7) and 
taxoter + cyclophosphamide (ТС) (n = 6); BC cells 
express P­gp (40–80%), and GST and МТ (0–50%).
3) The patients (n = 14) were treated according to the 
scheme gemcitabine + carboplatin; BC cells express 
P­gp (40–80%), GST (10–50%), and МТ (0–20%).
4) The patients (n = 16) were treated according 
to the scheme ТС + bevacizumab; BC cells express 
P­gp (40–80%), GST (5–20%) and МТ (50–80%).
As a result of a comparative analysis, it was estab­
lished that three­year survival of the patients of the 
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2nd, 3rd and 4th group was significantly higher than that 
of the control group. 
The results of the clinical observations showed that 
3­years relapse­free survival rate of the patients of the 
2nd, 3rd and 4th groups was 61.5%, 78.6% and 81.2% re­
spectively, vs 41.2% in the control group (p < 0.05) (Table). 
Analysis of overall survival of the patients with the triple­
receptor­negative BC has shown that in the 2nd, 3rd and 
4th groups it reach 84.4%, 92.6% and 93.8% respectively, 
vs 70.6% in the control group (p < 0.05). It is necessary 
to note that the application of scheme TC + bevacizumab 
was found to be the most efficient one. Thus, our study 
has shown the possibility to elevate the efficiency of poly­
chemotherapy by its individualization based on the expres­
sion patterns of Р­gp, GST and MT on tumor cells of the 
patients with the triple­receptor­negative BC. 
Table. Treatment schedules and survival rate of breast cancer patients
Group PCT Scheme 3-year survivalOverall Relapse-free
1 (control) (n = 17) АС/CMF 70.6% 41.2%
2 (n = 13) ТА/ТС 84.6%* 61.5%*
3 (n = 14) Gemcitabine + carboplatin 92.6%* 78.6%*
4 (n = 16) TC + bevacizumab 93.8%* 81.2%*
*Statistically significant compared to control group.
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